Spectral Medical Inc T.EDT

RE:RE:Prospective Investor Confusion abounds ....

[Inca2020]

I'm not sure... but I would think they would be in charge of keeping investors up to date.

Inca2020 wrote:

Isn't that the job of Spinnaker Capital Markets Inc.? 

 

mercedesman wrote: There currently is no investor presentation on the Spectral website...there has not been one for several weeks now...

The other information appears to be either out of date or in conflict with the most recent presentaion that was available at the time of the AGM, and or the prospectae that were used to raise funds (including the $ 50m Base Shelf Prospectus)

For example:

Currently the website tells prosective investors....

Sepsis affflicts "approximately 1,000,000 americans each year"  (yet other data, presentations, prospectus data suggested 1.7 M , which is based on years old/ out of date CDC data, does not include estimates for 2020 and beyond, nor does it appear to factor in a likely increase due to Covid-19)

" Toraymyxin..has been used effectively in more than 150,000 patients to date"   I thought that figure was revised much higher 170k 190k?

"Approximately one third of these patients progress to severe sepsis and septic shock, representing a significant unmet need and an approximately $3 billion market opportunity for Spectral."   But I thought recent presentations said $ 1.5B opportunity?  A billion here and a billion there - pretty soon we're talking about real money !


If I was a prospective investor, I would find the website somewhat confusing and contradictory to the other stuff that has been issued as part of legal requirements  (e.g prospectus, Sedar docs, etc.) and more recent investor presentaions (since removed).

And then there is the legitimate question of why the Baxter tranche # 1 ($ 5M USD) has not been recognized as revenue upfront when it is non-refundable?  A 9 year recognition period? In other words Q1 2020, not so imprssive as it could be? More justification/disclosure is surely required?

What guides prospective investors into this stock?  Does the SH IR (legacy) program only serve to confuse and drive prospective investors away FROM, not in TO, the stock? Paradigm Analyst report you say?  Who see's that?

What progress has been made on a higher OTC listing? A reverse split? A US Nasdaq listing? a spin-off of Dialco?  All likely significant value building events for shareholders.  Talk is cheap.  Where is the action?

The 5 to 10 extension of the Toray contract in conjunction with the Baxter negotiations/deal? You guys all remember that NR right?

I have yet to find a publicly traded Company that does less to attract new investor interest and inform existing shareholders (and I have likely invested in close to 1000 different Companies). Don't existing shareholders partially deserve some credit for plunking down their hard earned $, and for taking a (more in teh dark) risk alongside big inivestors? Shouldn't they be at least rewarded with consistent, accurate and timely data?

Why the degree of understatement?

A 25 year effort, $ 80 M spent on Trials, Warrants and Options up the whazoo, a DA with a mutlibillion dollar major player in the US, money to finish a confirmatory Trial, 2 FDA approvals, another one pending, a decade of CRRT/HD product development, a possible therapy to treat the most severe Covid patients suffering from various organ failures......just so a few guys can earn a solid T4 living before it drifts off into oblivion?

I hardly think so !

There's more to the story.  Time to tell it.

MM